Advances in the mechanism of action of the ring finger proteins family in breast cancer

doi:10.16352/j.issn.1001-6325.2026.01.0124

Abstract

Abstract: The ring finger proteins(RNFs) family not only function as E3 ubiquitin ligases involved in protein degradation, but also plays crucial roles in regulating various cellular processes such as proliferation, apoptosis, DNA damage repair, tumor immune escape and epigenetic modification. RNFs promote breast cancer cell proliferation and survival by activating specific signaling pathways and modulating gene expression. By facilitating DNA damage repair, they contribute to genomic stability and enhance resistance to therapy. In the context of tumor immune evasion, RNFs mediate the ubiquitination of immune checkpoint molecules, thereby inhibiting anti-tumor immune responses. Furthermore, in epigenetic regulation, RNFs influence DNA methylation and histone modifications to suppress the expression of tumor suppressor genes, thus promoting cancer cell proliferation and drug resistance. Targeting RNFs may inhibit tumor growth and improve therapeutic outcomes in breast cancer.

Key words: ring finger proteins, breast cancer, ubiquitination, therapeutic target

CLC Number:

R737.9

LI Binfeng, LYU Fayou, YI Huijun, LYU Lyu. Advances in the mechanism of action of the ring finger proteins family in breast cancer[J]. Basic & Clinical Medicine, 2026, 46(1): 124-128.

References

[1]Tang CT, Liu Z de, Wang P, et al. Lipopolysaccharide-regulated RNF31/NRF2 axis in colonic epithelial cells mediates homeostasis of the intestinal barrier in ulcerative colitis[J]. Cellular Signalling, 2024, 124:111480. doi:10.1016/j.cellsig.2024.111480.
[2]Liu Y, Chen P, Qi D, et al. Glaucocalyxin a inhibits the malignancies of gastric cancer cells by downregulating MDM2 and RNF6 via miR-3658 and the SMG1-UPF mRNA decay pathway[J]. Front Oncol, 2022, 12:871169. doi:10.3389/fonc.2022.871169.
[3]Liu Y, Ouyang L, Mao C, et al. Inhibition of RNF182 mediated by bap promotes non-small cell lung cancer progression[J]. Front Oncol, 2023, 12:1009508. doi:10.3389/fonc.2022.1009508.
[4]Zou L, Sun L, Hua R, et al. Degradation of ubiquitin-editing enzyme A20 following autophagy activation promotes RNF168 nuclear translocation and NF-κB activation in lupus nephritis[J]. J Innate Immun, 2023, 15:428-441. doi:10.1159/000527624.
[5]Xue C, Meng H, Niu W, et al. TRIM28 promotes tumor growth and metastasis in breast cancer by targeting the BRD7 protein for ubiquitination and degradation[J]. Cell Oncol, 2024, 47:1973-1993. doi:10.1007/s13402-024-00981-3.
[6]Zhu J, Zhao C, Zhuang T, et al. RING finger protein 31 promotes p53 degradation in breast cancer cells[J]. Oncogene, 2016, 35:1955-1964. doi:10.1038/onc.2015.260.
[7]Chen X, Su W, Chen J, et al. RNF123 inhibits cell viability, cell cycle and colony formation of breast cancer by inhibiting glycolysis via ubiquitination of PFKP[J]. Naunyn-Schmiedeberg's Arch Pharmacol, 2024. doi:10.1007/s00210-024-03723-2.
[8]Li Z, Li Y, Han D, et al. CircRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells[J]. Cell Death Dis, 2023, 14:482. doi:10.1038/s41419-023-06006-5.
[9]Yuan L, Li X, Yang H, et al. The ubiquitin ligase RNF2 stabilizes ERα and modulates breast cancer progression[J]. Hum Cell, 2022, 36:353-365. doi:10.1007/s13577-022-00810-5.
[10]Han D, Wang L, Long L, et al. The E3 ligase TRIM4 facilitates SET ubiquitin-mediated degradation to enhance ER-α action in breast cancer[J]. Adv Sci, 2022, 9:2201701. doi:10.1002/advs.202201701.
[11]Zheng M, Liu W, Zhang R, et al. E3 ubiquitin ligase BCA2 promotes breast cancer stemness by up-regulation of SOX9 by LPS[J]. Int J Biol Sci. 2024, 20:2686-2697. doi:10.7150/ijbs.92338.
[12]Hu A, Zhang L, Cao L, et al. RNF135 promotes the stemness of breast cancer cells by ubiquitinating and degrading DDX58[J]. Transl Oncol, 2025, 54:102321. doi:10.1016/j.tranon.2025.102321.
[13]Huang Y, Zou Y, Jie Z. RNF6 promotes the migration and invasion of breast cancer by promoting the ubiquitination and degradation of MST1[J]. Exp Ther Med, 2021, 23:118. doi:10.3892/etm.2021.11041.
[14]Zhou R, Ding Y, Xue M, et al. RNF181 modulates hippo signaling and triple negative breast cancer progression[J]. Cancer Cell Int, 2020, 20:291. doi:10.1186/s12935-020-01397-3.
[15]Hu Y, Jiang N, Wang X, et al. Systematic pan-cancer analysis of RNF186 with potential implications in progression and prognosis in human cancer[J]. Life Sci, 2024, 338:122389. doi:10.1016/j.lfs.2023.122389.
[16]Liu W, Zheng M, Zhang R, et al. RNF126-mediated MRE11 ubiquitination activates the DNA damage response and confers resistance of triple-negative breast cancer to radiotherapy[J]. Adv Sci, 2023, 10:2203884. doi:10.1002/advs.202203884.
[17]Pan Y, Yang Y, Huang R, et al. Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors[J]. Breast Cancer Res, 2022, 24:92. doi:10.1186/s13058-022-01586-0.
[18]Zhu Q, Huang J, Huang H, et al. RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination[J]. Nat Commun, 2021, 12:6653. doi:10.1038/s41467-021-27048-3.
[19]Krishnan R, Lapierre M, Gautreau B, et al. RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells[J]. Nucleic Acids Res, 2023, 51:10484-10505. doi:10.1093/nar/gkad733.
[20]Xu C, Li C, Chen J, et al. R-loop-dependent promoter-proximal termination ensures genome stability[J]. Nature, 2023, 621:610-619. doi:10.1038/s41586-023-06515-5.
[21]Yao Y, Gong G, Guo Z, et al. A pan-cancer analysis of ring finger protein 135 and its relationship to triple-negative breast cancer proliferation and metastasis[J]. Aging, 2022, 14:9758-9772. doi:10.18632/aging.204429.
[22]Yang H, Xue M, Su P, et al. RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast cancer[J]. J Exp Clin Cancer Res, 2022, 41:364. doi:10.1186/s13046-022-02576-y.
[23]Wegwitz F, Prokakis E, Pejkovska A, et al. The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis[J]. Cell Death Dis, 2020, 11:873. doi:10.1038/s41419-020-03081-w.
[24]Lyu Y, Yang Y, Talwar V, et al. Hypoxia-inducible factor 1 recruits FACT and RNF20/40 to mediate histone ubiquitination and transcriptional activation of target genes[J]. Cell Rep, 2024, 43:113972. doi:10.1016/j.celrep.2024.113972.
[25]Dong Q, Gong C, Jiang Q, et al. Identification of differentially expressed tumour-related genes regulated by UHRF1-driven DNA methylation[J]. Sci Rep, 2024, 14:18371. doi:10.1038/s41598-024-69110-2.